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A Deer in the Mist
 
The snow-white Yosemite Valley from the freezing cold the 
night before woke up to the warm midday sun of December, 
revealing a myriad of colours - yellow, amber, red, green and 
blue.  Yet the stag stood out above all else and instantly lured 
me to brake my car, rush down to the back for my gear and 
capture this split second on Kodachrome 64.
At the same time, two boys approached the animal from the left 
and a Park Ranger cried caution on the right.  Before I could 
press the shutter again, all were gone leaving the trees, the 
misty colours and icicles melting and falling through the rays of 
light - beautiful still but a far cry from just a moment ago.  
My Nikon F2 did not fail me on this occasion and in turn, it 
never fails to remind me of what George Eliot once wrote - the 
golden moments in the stream of life rush past us and we see nothing 
but sand; the angels come to visit us, and we only know them when 
they are gone! 
Dr. Dawson FONG
MBBS(HK), FRCS(Edin), 
FCSHK, FHKAM(Surgery)
Chief of Service and Consultant 
Neurosurgeon, Department of 
Neurosurgery, NT West Cluster
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Editorial 
Dr. Ming-kwong YIU 
The price to pay for modern men to be able to live longer is 
accomplished with ageing and its associated problems. Prostate 
disease is definitely one of them. Men either urinate too often, too 
soon, too slow or not enough after they turn into their middle age. 
A survey done by the Hong Kong Urological Association previously 
revealed more than 40% of the male population in Hong Kong older 
than 60 years old suffered from moderate to severe Lower Urinary 
Tract Symptoms (LUTS). Cancer development in prostate glands is 
another source of concern in this same group of aged population. The 
incidence of prostate cancer is on a rising trend in Hong Kong. Data 
from the Hong Kong Cancer Registry showed that prostate cancer 
is already ranked the third commonest cancer and the fifth killing 
cancer of the Hong Kong male population. Prostate cancer could be 
completely asymptomatic at its early stage, and many of these cases 
were discovered during the course of urological consultation or blood 
screening test for Prostate Specific Antigen (PSA). 
The treatment of Prostate diseases is evolving for a better clinical 
outcome, either with drugs, radiotherapy, surgery or other alternative 
gimmicks; yet there are still lots of choices and controversies. This is 
a reflection of our limitation in the knowledge we have in applying it 
to treat our patients with either benign (prostatitis, BPH) or malignant 
conditions (prostate cancer). 
From the clinician’s perspective, there are a lot of questions we 
need to answer before we give counselling advice or start managing 
our patients for these common problems. Is “prostatitis” a genuine 
infection or just a pain symptom in the perineum originates from 
supra-tentorial affection? Whether the LUTS in patients with “BPH” is 
solely caused by the hyperplasia prostatic obstruction or degenerative 
change of the bladder with overactivity (Over Active Bladder OAB) 
being the culprit? Will PSA screening in middle aged or thereafter 
improve survival if cancer is discovered during subsequent diagnostic 
workup and follow up treatment. Do all prostate cancers kill? If not, 
how could we differentiate the “kitten” from the “loin”? And what is 
the latest development in treating prostate cancer disease?
I hope our readers, after reading through the articles in this edition 
of the Medical Dairy, could gain more in depth knowledge on these 
common problems. This could in turn assist in managing our patients 
in clinical practice. 
Editor
www.apro.com.hk
Dr. Ming-kwong YIU 
MBBS, FRCS(Ed.), FSCHK, Dip Urol (Lond), FHKAM(Surgery) 
Consultant Urologist, Division of Urology, Department of Surgery, 
Princess Margaret Hospital
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Pathology and Medical Therapy of 
Benign Prostatic Hyperplasia
Dr. Steve Wai-hee CHAN
Division of Urology, Department of Surgery, Queen Elizabeth Hospital
Dr. Steve Wai-hee CHAN
Introduction
Benign Prostatic Hyperplasia (BPH) is a progressive 
condition characterised by prostate enlargement 
accompanied by lower urinary tract symptoms (LUTS)1,2. 
It contributes to, but is not the sole cause of LUTS. It is 
well known that BPH and the resultant LUTS is very 
common in elderly men3,4 and has a great impact on 
the patients’ quality of life5. It was estimated that in the 
male population, a histological prevalence at autopsy of 
50% in men aged 50-60 years and of 90% over 80 years6 
was seen. 75% of men > 50 years old had symptoms 
arising from BPH, and 20-30% of men reaching 80 years 
old required surgery1,2. Despite the fact that BPH is 
one of the commonest diseases that are managed by 
urologists and it has a big impact on public health, the 
aetiology and pathophysiology are still not yet clear. 
Aetiology
Several mechanisms are now believed to be important 
in the development and progression of BPH:
Tissue Remodelling
McNeal demonstrated that BPH first develops in the 
periurethral transition zone of the prostate7 and all the 
BPH nodules develop either in the transition zone or in 
the periurethral region. Although early transition zone 
nodules appear to occur either within or immediately 
adjacent to the preprostatic sphincter, as the disease 
progresses and the number of prostatic nodules 
increases, they can be found in almost any portion of the 
transition or periurethral zone. The nodular enlargement 
is androgen-dependent and the tissue remodelling 
involves both the epithelium and fibromuscular 
stroma8,9. These nodules are characterised by a reduced 
epithelium-to-stroma ratio, determined by an imbalance 
between growth and death programmes of stromal 
cells, leading to increased final stromal volume10,11,12. 
The underlying mechanism may be attributable to the 
involvement of enhanced expression of anti-apoptotic 
cell death mechanisms in the human prostate, resulting 
in a growth imbalance in favour of cell proliferation that 
might ultimately support hyperplasia11,13,14.
Hormonal Alterations
Although androgens do not cause BPH, the development 
of BPH requires the presence of testicular androgens 
during prostate development, puberty and ageing. 
Despite the fact that the serum level of testosterone 
decreases with age, it is known that the intra-prostatic 
levels of the active metabolite dihydrotestosterone 
(DHT) as well as the androgen receptor (AR) remain 
high15,16. DHT is predominantly generated by prostatic 
5-alpha reductase, which is present in fibroblasts of the 
stroma and in basal epithelial cells and recent androgen-
responsive genes studies showed that androgen 
signalling is significantly elevated in hyperplastic tissue 
relative to the adjacent normal prostate17.
Inflammation
BPH has been frequently observed to be associated 
with chronic prostatitis and now chronic inflammation 
is believed to support the process of fibromuscular 
growth in BPH18. Many studies including major studies 
like the Reduction by Dutasteride of Prostate Cancer 
Events (REDUCE) trial and the subgroup analysis of the 
Medical Therapy of Prostate Symptoms Study (MTOPS) 
found correlation between inflammation of the prostate 
and BPH19,20. It was proposed that inflammation of the 
prostate caused tissue injury, and cytokines produced 
by the inflammatory cells might serve to drive local 
growth factor production and angiogenesis in the tissue 
as a wound healing process, resulting in tissue growth.
Metabolic Syndrome
BPH and the metabolic syndrome are believed to be 
associated according to recent studies. The metabolic 
syndrome is defined as abdominal obesity associated 
with hyperinsulinaemia, insulin resistance and two 
additional cardiovascular risk factors21. Diabetes 
mellitus, hypertension, obesity and low high-density 
lipoprotein cholesterol (HDL-C) levels constitute risk 
factors for the development of BPH22,23,24.
Pathophysiology
According to the classical model and belief, the size 
of the prostate increases with BPH, thus resulting in 
the obstruction of the urine flow that accounts for the 
LUTS. Therefore, the logic was previously surgery like 
prostatectomy or drugs that can reduce the resistance to 
urine flow can resolve LUTS. However, it is now known 
that the pathopysiology of BPH is much more complex: 
prostatic hyperplasia increases urethral resistance, 
resulting in compensatory changes in bladder function. 
The obstruction-induced changes in detrusor function, 
compounded by age-related changes in both bladder 
and nervous system function, lead to urinary frequency, 
This article has been selected by the Editorial Board of the Hong Kong Medical Diary for participants in the CME programme of the Medical 
Council of Hong Kong (MCHK) to complete the following self-assessment questions in order to be awarded CME credit under the programme upon 
returning the completed answer sheet to the Federation Secretariat on or before 30 June 2011. The CME accreditation is in application. The number 
of CME credit is subject to the final decision of the organisations.
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urgency and nocturia, the most bothersome LUTS. This 
concept can at least be partly proven from the study by 
Neal et al, which showed prostatectomy could resolve 
the emptying problem of LUTS but not the storage 
problem25. 
Half of the stromal hyperplasia is composed of smooth 
muscle elements26 and it was believed that the enlarged 
prostate caused obstruction via both dynamic and static 
mechanisms27. The static component was due to the 
physical presence of the prostate obstructing the urine 
stream within the prostatic urethra and the dynamic 
obstruction was thought to be the result of smooth 
muscle hyperplasia and contraction28 and was mediated 
by alpha 1 adrenoceptor subtype29.
As in most chronic diseases, BPH is progressive: it 
requires a long period to evolve from earlier tissue 
alterations to clinical onset with LUTS30 or if untreated, 
it is often complicated with bladder dysfunction and 
hypertrophy possibly leading to acute urinary retention 
(AUR). 
Medical Therapy 
Current strategies for treating men with LUTS are 
watchful waiting, pharmacologic therapies and surgery 
and this article will focus on medical therapy.
Phytotherapy
The most commonly used phytotherapies for BPH 
are extracts of Serenoa repens (sau palmetto), thought 
to have antiandrogenic, anti-proliferative and anti-
inflammatory effects, and extracts of the African plum 
tree’s bark. Many patients found phytotherapies 
attractive as they have low side effects. A randomised, 
double-blind, placebo-controlled study did not show 
any benefit of Serenoa repens over the placebo arm in 
respect to symptom relief at 1 year31.
Alpha Blockers Monotherapy
There are 3 subtypes of the alpha 1 adrenergic receptor: 
the alpha 1a, alpha 1b and alpha 1d receptors. The 
alpha 1a receptor subtype is the most dominant in 
the prostate and contraction of the human prostate is 
mediated predominantly by alpha 1a-adrenoceptors32. 
Therefore selective blocking of this subtype can result in 
the reduction of the symptoms due to BPH by relaxing 
smooth muscle tone in the prostate and bladder neck. 
Alpha 1b receptor blockade is to be avoided as it is 
present in the capacity vessels and is responsible for 
hypotension and undesirable cardiovascular side 
effects33. Other side effects of the alpha receptor blockers 
apart from orthostatic hypotension include dizziness, 
asthenia and nasal congestion. A unique side effect 
of this group of medications is the intraoperative 
floppy iris syndrome, which is characterised by miosis, 
iris billowing and prolapse in patients undergoing 
cataract surgery who have taken or are currently taking 
alpha receptor blockers. Therefore, it is critical for all 
patients taking alpha-1 receptor blockers to alert their 
ophthalmologist if they are contemplating cataract 
surgery.
Alpha blockers are one of the most effective forms of 
medical treatment to reduce symptoms in most men 
with LUTS suggestive of BPH. They are considered 
an appropriate option by the American Urological 
Association (AUA)34 and a large number of clinical 
studies have demonstrated its efficacy. Typically 
significant symptom relief could be obtained within 
1-2 weeks of starting therapy and reduce symptom 
scores by 5-8 points on the AUA-SI scale, with no clear 
differences between the agents within the class34,35. 
Another important clinical use of alpha blockers is to 
treat acute urinary retention. A randomised, double 
blind, placebo-controlled study showed that starting 
an alpha blocker after catheterisation in acute urinary 
retention increased the chance of successful trial without 
catheter (TWOC)36.
Selective Short-acting Alpha 1 Blockers
Prazosin was the first selective alpha 1 antagonist 
investigated for BPH. It was shown to be better tolerated 
than the non-selective alpha blocker phenoxybenzamine37 
but still it requires multiple daily dosing, and side 
effects of postural hypotension is sill problematic. 
Despite the fact that the side effects are quite prominent, 
Prazosin is still commonly prescribed in Hong Kong 
due to its low cost.
Long Acting Selective Alpha 1 Blockers
Terazosin was the first selective long-acting alpha 
1 blocker investigated for the treatment of BPH. A 
multicentre, randomised, placebo-controlled trial 
showed statistically significant improvements over 
symptoms and peak flow rate38. Doxazosin was the 
second alpha 1 blocker approved by the FDA for 
treating BPH. Two multicentre, randomised trials were 
performed comparing various doses of doxazosin with 
placebo39,40. Although doxazosin has a longer half-life, 
the studies did not confirm any clinical advantage. Both 
terazosin and doxazosin exhibited lowering of blood 
pressure only in those men who were hypertensive at 
baseline41,42 which was desirable. The more common side 
effects of terazosin and doxazosin included dizziness 
(10-15%), fatigue (8%) and hypotension (1.5-4%).
Tamsulosin was the third alpha 1 blocker to be 
approved for the treatment of BPH. It was the first 
subtype selective alpha 1 antagonist and was tenfold 
more selective for the alpha 1a versus alpha 1b subtype43 
but there was no demonstrable subtype selectivity of 
tamsulosin for the alpha 1a versus alpha 1d subtypes. 
Trials showed 0.4mg tamsulosin was able to achieve 
significant improvements in symptom scores and peak 
flow rate without the need for dose titration, in contrary 
to doxazosin and terazosin44,45. However, the side effect 
profile of tamsulosin is quite similar to doxazosin and 
terazosin with dizziness, fatigue and hypotension, with 
the additional side effect of retrograde ejaculation or 
anejaculation46. 
Alfuzosin 10mg daily is the fourth alpha 1 blocker 
approved by FDA for the treatment of symptomatic 
BPH and it has no selectivity for the alpha 1 subtype. 
It has good tolerability and has significant clinical 
improvement in LUTS without dose titration47,48. The 
AUA Guidelines Committee concluded that alfuzosin 
has comparable clinical efficacy with tamsulosin and 
the other approved alpha blockers but does not cause 
ejaculatory dysfunction49.
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Silodosin a newer selective alpha 1a receptor blocker 
and effective for both storage and voiding symptoms in 
BPH patients versus placebo, especially in patients with 
severe symptoms (IPSS >= 20)50. Marks et al reported a 
pooled analysis of two phase 3 randomised trials which 
showed rapid significant improvement within 3-4 days 
of initiation of silodosin51. The efficacy of the drug was 
also supported by urodynamic effect studies which 
showed improvement in peak flow rate, maximal bladder 
capacity and reduction of detrusor overactivity 52. 
5 Alpha Reductase Inhibitors
The main circulating androgen, testosterone, is 
converted to di-hydroxytestosterone (DHT) by the 
enzyme 5-alpha reductase (5AR) and DHT is involved 
in the development of BPH. There are 2 isoenzymes 
of 5ARs: finasteride inhibits type 2 and dutasteride 
inhibits both type 1 and 2 isoenzymes of 5AR. They 
can reduce the intraprostatic DHT by 80-90% and lead 
to atrophy of the prostate and subsequently shrinkage 
in prostate volume by 25% in 2 years and reduce the 
serum prostate specific antigen (PSA) by approximately 
50% over 6 months53. In the patients whose PSA are 
monitored, doubling the PSA value of the patients on 5 
AR inhibitors is necessary. IPSS can be reduced by IPSS 
3-4 points and sustained improvement of peak flow rate 
by 2ml/s and reduce the risk of acute urinary retention 
as well as BPH-related surgery by greater than 5054,55. 
The symptom relief from 5ARIs is most pronounced in 
larger glands (>40 ml) and the AUA Guidelines do not 
recommend them for men who do not have evidence of 
prostate enlargement56.
5ARIs generally provide less symptomatic improvement 
compared to alpha-adrenergic receptor blockers and 
their onset of action is slow and occurs at 3-6 months but 
they reduce the long-term risk of progression to acute 
urinary retention and surgery54,55. The most notable side 
effects are sexual side effects: decreased libido, erectile 
dysfunction and ejaculatory disorder. Rarely, some men 
note breast tenderness. 
Combination of Alpha Blockers and 
5ARs
Alpha blockers and 5ARIs
Theoretically, alpha blockers provide early relief, 
whereas 5ARIs provide long-term disease management 
and this concept was confirmed with the Medical 
Therapy of Prostatic Symptoms MTOPS trial in 
200357. MTOPS enrolled 3057 men with LUTS and 
clinical BPH and randomised them to treatment with 
placebo, doxazosin, finasteride, or a combination of 
doxazosin and finasteride over a period of 4 to 5 years. 
The combination treatment resulted in significantly 
better outcomes in terms of overall risk of clinical 
progression (defined as an increase above baseline of 
>=4 points in the AUA-SI, AUR, urinary incontinence, 
renal insufficiency or recurrent urinary tract infection) 
compared with either doxazosin or finasteride alone. 
But this observation was significant only in patients with 
a baseline prostate volume <25ml58. The Combination of 
Avodart and Tamsulosin (CombAT) study investigated 
the effects of combination therapy with dutasteride and 
tamsulosin as opposed to each as monotherapy and that 
showed combination therapy had significant benefits for 
patients in terms of reduction in symptoms and prostate 
volume59.
Although combination therapy has the benefits from 
both alpha blockers and 5AR inhibitors, the problem 
with this combination therapy is cost and the patients 
may suffer from sides effects from either or both of these 
drugs.
Anticholinergics
Current understanding about the pathophysiology 
of BPH shows the change in bladder function in 
association with BPH constitutes an important factor in 
the development and progression of bothersome LUTS 
in BPH. Anticholinergics block the parasympathetic 
pathway, thereby abolishing or reducing the severity 
of detrusor muscle contractions. It is believed that 
storage symptoms are more bothersome to the patients 
and in patients with prominent overactive bladder 
symptoms, anticholinergic drugs can be considered60. 
The Tolterodine and Tamsulosin in Men with LUTS 
and Overactive Bladder study recruited nearly 900 
patients into placebo versus tamsulosin 0.4mg versus 
extended-release tolteridine 4mg versus a combination 
of tolterodine and tamsulosin61. The conclusion was 
that the patients with voiding and storage problems did 
not respond to monotherapy with either alpha blockers 
or anti-muscarinic agents but had a statistically and 
clinically significant treatment benefit from combination 
therapy of an alpha blocker and an antimuscarinic 
agent. Side effects experienced by the patients were 
typical of the agents including dry eyes and mouth, 
constipation and retention of urine but the incidence of 
acute urinary retention was low. Similar improvement 
in symptoms was observed in patients who failed 
previous alpha blocker treatment62 and after treatment 
with alpha blocker and 5AR inhibitor combination 
therapy by the addition of anticholinergics63.
PDE-5 Inhibitors
There is growing interest in using phosphodiesterase 5 
(PDE-5) inhibitors in the management of BPH but the 
precise mechanism of action is not yet fully understood. 
Sildenafil  and Tadalafil  were found to provide 
improvement of IPSS by 6-7 points versus placebo but 
neither sildenafil and tadalafil improved the peak flow 
rate significantly64,65. The combination of alpha blocker 
and PDE-5 inhibitor has also been studied and the 
patients in the combination group of receiving both 
alfuzosin 10mg daily and sildenafil 25mg daily had the 
greatest benefits in IPSS, peak flow rate and erection 
compared with either drug alone66. However, PDE-
5 inhibitors have officially been licensed only for the 
treatment of erectile dysfunction and pulmonary arterial 
hypertension. Treatment beyond these indications is 
experimental.
Conclusions
Medical therapy is indicated in patients with bothersome 
lower urinary tract symptoms and alpha blockers are 
usually the first option due to its rapid onset of action. 
In those patients with persistent bothersome storage 
symptoms, addition of an anti-muscarinic agent can 
be considered after assessment with post void residual 
volume measurement to rule out baseline urinary 
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retention. The 5AR inhibitors are usually prescribed 
for long term treatment, especially those with bigger 
prostate volume. The patient’s individual condition and 
wish need to be evaluated together with consideration 
about the benefits, costs and side effects of the drug 
to facilitate decision making in determining the best 
medical treatment for the patient.
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Pathology and Medical Therapy of Benign Prostatic Hyperplasia
Dr. Steve Wai-hee CHAN
Division of Urology, Department of Surgery, Queen Elizabeth Hospital
1.  Androgens cause BPH 
2.  Abdominal obesity, hyperinsulinemia and hypertension constitutes the metabolic syndrome 
3.  BPH causes obstruction by both dynamic and static components
4.  The use of alpha blockers is useful in acute urinary retention (AUR)
5.  Doxazosin & Terazosin are selective for alpha 1a receptor subtype
6.  Alfuzosin is known to cause anejaculation
7.  5ARIs are fast acting
8.  There are 2 isoenzymes of 5 AR
9.  Combination of alpha blocker and 5AR Inhibitors can reduce the risk of BPH progression
10.One of the risks of the use of anticholinergics is intraoperative floppy iris syndrome
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Management of Prostatitis
Dr. Richard LO
MD(UCLA), MCPS(Manitoba), FCSHK, American Board of Urology, FHKAM(Surgery) 
Consultant Surgeon, Pedder Clinic 
Dr. Richard LO
The term “Prostatitis” has been used to describe a 
whole constellation of genitourinary symptoms in men. 
Men with pain or discomfort from the subumbilical 
area to the groin, with or without voiding symptoms, 
are all labelled as having Prostatitis.  This is a result of 
poor understanding of the aetiology of these painful 
syndromes, and confusion over bacterial infection as a 
real aetiology that caused these symptoms.
Prostatitis is a rather common ailment amongst men, 
with the prevalence estimated to be 9 to 16% of the male 
population, or 3.8/1000 person-years.  At any one time, 2 
to 10% of men will experience prostatitis-like symptoms. 
Of those afflicted, 1 in 4 will have more than one episode 
per year, with 16% of the patients having persistence of 
their symptoms.  It is estimated that in some countries, 
prostatitis comprises 3 to 12% of a urologist’s outpatient 
workload.
The National Institute of Health classified prostatitis 
into four main categories:
Category I – Acute Bacterial Prostatitis
Category II – Chronic Bacterial Prostatitis
Category III – Chronic Pelvic Pain Syndrome (CPPS)
Category IIIA – Inflammatory CPPS
Category IIIB – Non-inflammatory CPPS
Category IV –Asymptomatic Inflammatory Prostatitis
Categories I and II are associated with bacterial 
infections of the urine, while the aetiology of the latter 
two are obscure.  Microbiological, immunological, 
neurological, inflammatory and psychological causes, 
singly or in combination, have been implicated 
but never conclusively proven in the CPPS group. 
Statistically, Categories I and II account for no more 
than 10-15% of the group.
The sine qua non in the diagnosis of bacterial prostatitis 
is a documented bacteriuria.  Acute bacterial prostatitis 
is heralded by high fevers, chills, perineal pain, severe 
dysuria and other lower urinary tract symptoms (LUTS). 
Digital rectal examination will show an enlarged and 
exquisitely tender prostate.  The patient is acutely ill and 
appears toxic.  Urine microscopy will show pyuria and 
the culture will reveal significant bacteriuria, usually 
a coliform of intestinal origin.  Management of acute 
bacterial prostatitis consists of empirical intravenous 
antibiotics, usually an aminoglycoside with a third-
generation cephalosporin or carbopenam if the local 
sensitivity profile so dictates.  With deferescence and 
clinical improvement after IV antibiotics, the patient 
can be switched to oral antibiotics according to the 
sensitivity profile of the particular organism, for another 
three to four weeks.  This is the only opportunity to 
avert an acute bacterial prostatitis progressing to the 
chronic version. 
In the normal, non-inflamed state, the blood-prostate 
barrier blocks diffusion of most serum contents from 
entering the prostate. In acute bacterial prostatitis, 
however, this barrier to antibiotics diffusion is broken 
down because of the intense inflammation, and provides 
the only scenario in which bacteria in the prostate could 
be successfully eradicated. 
The single most important feature in the diagnosis 
of chronic bacterial prostatitis is the recognition of 
a chronic, relapsing bacterial cystitis, with the same 
organism and identical sensitivity pattern.  As the 
bacteria are now resident in the prostate and are 
‘protected’ by this impregnable blood-prostate barrier 
layer, they will not be exposed to any antibiotic, 
and therefore there will be no selection of resistant 
organisms. The patient may have recollection of an 
episode resembling acute bacterial prostatitis, but 
the recurrent pattern is a helpful hint to the astute 
physician.  The symptoms, however, are much less 
pronounced, and usually consist of dysuria, frequency 
and urgency only.
Diagram 1 : Meares-Stamey 4-glass bacteriologic localisation
*Should be negative in between infections
Further documentation of the bacteria originating 
from the prostate is needed to cinch the diagnosis.  The 
4-glass segmental urine culture described by Meares 
and Stamey, (Diagram 1) compares the bacterial colony 
counts in the midstream urine versus those in the 
prostatic fluid obtained by prostate massage (EPS), and 
the washout portion from the urethra after massage 
(VB3).  If there is a two-log increase (EPS/VB3 >> VB2), 
and the organism is identical to the one recovered from 
a midstream culture whilst infected, the diagnosis of 
chronic bacterial prostatitis is confirmed.  Treatment 
of chronic bacterial prostatitis, once proven, is actually 
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the simplest: as the organism and sensitivity profile 
are known. A midstream urine is sent for culture if 
practical. The patient is empirically prescribed a 3 to 
4-day course of a sensitive antibiotic, which should be 
sufficient. In the event the patient is still symptomatic 
after the antibiotic treatment, the possibility exists that 
a different offending organism had actually caused a de 
novo cystitis and it was not a recurrence of the original 
chronic bacterial prostatitis. (Remember there are over 
150 serotypes of E. coli!)
The main reason why patients do not improve after 
antibiotics is that it was not a bacterial infection after 
all. Those who fall into Category III or Chronic Pelvic 
Pain Syndrome (CPPS) have similar but yet dissimilar 
symptoms from their bacteria-infected cohorts. 
Groin, perineal, suprapubic and low back pain are 
common complaints. Lower urinary tract symptoms 
are sometimes associated features. The predominant 
symptom in all these patients, however, is pain. A 
single course of antibiotics is widely prescribed on 
first presentation of men with LUTS/CP/CPPS, and 
is acceptable practice in a primary care situation. If 
symptoms persist, it is mandatory to reassess the urine 
culture for bacteriuria, or at least microscopically 
for pyuria.  (Clinical ‘improvement’ after antibiotics, 
unfortunately, does not necessarily establish the 
diagnosis of bacterial infection.)  In the tertiary referral 
setting, it is not unusual to see patients who were 
prescribed a protracted course of multiple antibiotics, 
urinary analgesics and anxiolytics.
When a patient with suspected CPPS is referred, proper 
bacteriological studies with segmental urine cultures 
(after an appropriate washout period), and microscopic 
examination of the expressed prostatic secretion should 
be performed, to definitively rule out any bacterial 
origin.  If the cultures are negative, these patients are 
treated symptomatically and empirically.  Further use of 
antibiotics is futile.
α- adrenergic blockers have been shown, in randomised 
placebo-controlled studies, to have a modest benefit 
in selected patients. The subset who improves is 
usually those with recent onset of moderate to severe 
symptoms, and the treatment duration should be six 
weeks or more. A similar line of reasoning is used 
to recommend the use of skeletal muscle relaxants, 
but the response is variable and not supported by 
Level I evidence. Anti-inflammatory agents have been 
used, with limited success, but the analgesic effect 
may provide symptomatic relief to some. The use of 
hormonal treatment is based on the conviction that the 
prostate is the culprit.  Hormones should not be used in 
those without voiding type of LUTS.   
Physical therapy is used to supplement the shortcomings 
of medical treatment in CP/CPPS. These consist of 
prostate massage (long since abandoned by mainstream 
Urology), myofascial trigger point release, acupuncture 
and biofeedback. None of these have any proven 
efficacy or long-term benefits in large-scale, well-
designed studies. Similarly, it is extremely hazardous 
to recommend surgery or even minimally-invasive 
therapies like microwave thermotherapy, as the efficacy 
of these modalities remains unproven, and should only 
be used as a last ditch effort.  As the chief complaint and 
presenting symptoms are pain, pain amelioration is the 
main treatment goal in this group of patients. 
Dermatological Quiz
Dr. Lai-yin CHONG
MBBS(HK), FRCP(Lond, Edin, Glasg), FHKCP, FHKAM(Med)
Private Dermatologist
Dr. Lai-yin CHONG
This 30-year-old lady complained of recurrent, slightly itchy, pustular 
lesions at both palms (Fig a & b) and soles for 2-3 years. There were no 
lesions over the trunk and limbs. Nails and joints were all normal. She 
was a chronic smoker. Her past health was good otherwise. There was no 
significant drug history. Despite treatments with various topical potent 
steroids, the condition ran a wax and wane course.
Questions:
1.What is your clinical diagnosis?
2.What are the differential diagnoses?
3.What is the current understanding about its relationship with psoriasis?
4.How do you manage this condition?
Fig a:  Multiple discrete pustules at both palms
 Fig b:  Close-up of the lesions at the palm (See P.33 for answers)
Dermatological Quiz
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Surgical Options for Benign Prostatic 
Hyperplasia (BPH)
Dr. Chi-wai MAN
MBBS(HK), FRCS(Glasgow), FRCS(Edinburgh), FCSHK, FHKAM(Surgery), 
Diploma of Urology (London), Diploma of Child Health (London), LLB (Beijing)
Specialist in Urology
Chief of Service (Surgery) & Head of Urology Division, New Territories West Cluster, Hong Kong
Dr. Chi-wai MAN
Introduction 
In 1788 John Hunter first described the pathology 
of prostatic hyperplasia and its effects on the upper 
urinary tract. It took a century for the first suprapubic 
prostatectomy to be carried out in 1887 by AF McGill in 
Leeds (though Americans tend to claim credit to Fuller 
in New York in 1894.) The procedure was subsequently 
p o p u l a r i s e d  b y  S i r  Pe t e r  F r e ye r .  R e t r o p u b i c 
prostatectomy was first performed in 1908 but failed 
to attract attention until it was reintroduced by 
Terrence Millin in 1947. Since then, it remains the open 
operation of choice in UK for BPH. In 1909 H H Young 
introduced the transurethral cold punch resection of 
the prostate. M Stern introduced the first resectoscope 
in 1926 and shortly afterwards H Bumpus at Mayo 
Clinic introduced diathermy cutting and coagulation. 
In 1932 Joseph McCarthy introduced the fore-oblique 
lens, continuous irrigation and working element for 
resection, and performed the first series of transurethral 
resection of prostate (TURP) in a manner similar to 
what we are doing today. With further advances in 
technology and technique, TURP became established 
as the most commonly performed operation for BPH, 
and the open procedures are relegated only to situations 
where TURP are difficult or risky. This combination 
essentially formed the gold standard of surgery for 
BPH we are still adopting today. However, TURP is 
not without its complications. It keeps on evolving in 
technology under pressure for fewer complications. 
Other new technologies also sprang up in the last two 
decades utilising other forms of energy to achieve tissue 
destruction or removal in BPH. Many such techniques 
came and went. However, some stay as useful adjunct 
to the gold standard of TURP with open surgery back 
up, and appear promising as new directions for further 
evolution of intervention for BPH. This article orientates 
the reader through the myriad of contemporary 
procedures Hong Kong urologists are practising or have 
come across.    
When should Surgery be Considered 
as an Option in Patients with BPH?
According to the EAU (European Association of 
Urology) guidelines for BPH, the most frequent 
indication for surgical management is bothersome 
LUTS refractory to medical management. The following 
complications of BPH are considered strong indications 
for surgery:
- Refractory urinary retention
- Recurrent urinary retention
- Recurrent haematuria refractory to medical treatment    
   with 5alpha reductase inhibitor.
- Renal insufficiency
- Bladder stones
Large residual volume may also be an indication for 
surgery but there is great intra-individual variability 
and a limit requiring intervention has not been defined. 
The NICE (National Institute of Clinical Excellence) 
guidelines in 2010 for LUTS in men reiterate the need 
to offer surgery only if voiding symptoms are severe 
or if drug treatment and conservative management 
options have been unsuccessful or are not appropriate. 
However, the AUA (American Urological Association) 
guidelines opine that medical therapy is not a 
requirement for patients to consider operation because 
some patients may wish to have the most effective 
therapy as a primary treatment if their symptoms are 
particularly bothersome. The decision to elect surgery 
as the treatment alternative is based upon the patient’s 
own views of treatment risks versus benefits.
What are the Standard Surgical Options 
and What are their Limitations?
TURP, TUIP (Transurethral incison of prostate) and 
open prostatectomy are the standard surgical options.
TURP
TURP is the most commonly performed operation 
for bladder outflow obstruction. It involves the 
surgical removal of the prostate’s inner portion via 
an endoscopic approach through the urethra, with no 
external skin incision. A cystoscope with a fore-oblique 
lens and a tungsten resecting loop working on high 
frequency electric current is used for cutting the prostate 
tissue into small chips and for coagulating bleeders 
resulting from the resection. The resecting loop serves as 
a monopolar electrode and a circuit through the patient 
is completed with a patient plate returning current to 
the diathermy machine. Usually, 1.5% glycine is used 
as a non-conducting irrigant that will neither result in 
haemolysis or caramelisation (as sugar solutions do). 
Resected tissue chips are then removed from inside the 
bladder by flushing with evacuators. 
The Veterans Affairs (VA) Cooperative Study remains 
the most definitive published study of the efficacy and 
safety of TURP. The VA Cooperative Study found a 
1% risk of urinary incontinence and a decline sexual 
function of 6.5% similar to the incidence in the watchful 
waiting group. Other complications include irritative 
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voiding symptoms, bladder neck contracture, need 
for blood transfusion, infection and haematuria. The 
mortality of contemporary series is around 0.25%. One 
unique complication of TURP is the TUR syndrome, 
a dilutional hyponatraemia that occurs when the 
irrigant solution is absorbed into the blood stream. This 
occurred in 2%. The need for transfusion ranged from 
2 to 5%. The risks of TUR syndrome and significant 
bleeding increases with the size of the gland. 1, 2 
According to the recent release of SOMIP (Surgical 
Outcome Monitoring & Improvement Programme) 
results of the HA Hospitals, among 2669 cases of 
prostatectomy, mostly TURP, done over one year, the 
30 day mortality was 0.5%, and 6.6% had complications. 
The commonest complications were urinary tract 
infection and systemic sepsis. 0.8% had clot retention 
and 0.08% had bleeding requiring more than 4 units 
of transfusion within 72 hours of surgery. The median 
postoperative length of stay was 3 days.
Currently monopolar TURP remains the gold standard 
surgery for BPH. TURP comprises 95% of all surgical 
procedures and is the treatment of choice for prostate 
sized 30-80ml. Open prostatectomy is reserved for very 
large prostates or those with large bladder calculi. For 
small prostates TUIP has been associated with fewer 
complications. 
TUIP 
TUIP is an endoscopic surgical procedure limited to 
the treatment of smaller prostates 30ml or less with no 
middle lobes. Using a Collin’s knife an incision is made 
at 5 & 7 o’clock positions or on one side of the midline 
only. It starts just distal to the ureteric orifice and ends 
just proximal to the verumontanum. One or two cuts are 
made in the prostate and the prostate capsule, reducing 
constriction on the urethra. In appropriate patents TUIP 
results in similar symptomatic improvement as TURP. 
TUIP has a lower incidence of complications, minimal 
risk of bleeding and blood transfusion, decreased risk 
of retrograde ejaculation and shorter operating time 
and hospital stay. However there is a higher long-term 
failure rate.3
Open Prostatectomy
Open prostatectomy involves the surgical removal 
(enucleation) of the inner portion of the prostate 
via an incision in the lower abdominal area. Open 
prostatectomy is the treatment of choice for large 
glands over 80-100ml, associated complications such 
as large bladder stones, or if resection of the bladder 
diverticulum is indicated. With open enucleation of the 
adenoma there is more complete removal of adenoma 
and thus a lower retreatment rate, and TUR syndrome 
is completely avoided. However, the downsides 
include a midline incision, long hospital stay and more 
perioperative bleeding. 
2 surgical approaches to open prostatectomy are 
in common use: classical transvesical and Millin’s 
retropubic approaches.
Suprapubic prostatectomy or transvesical prostatectomy 
consists of the enucleation of the hyperplastic prostatic 
adenoma through an extraperitoneal incision of the 
lower anterior bladder wall. A suprapubic approach is 
ideal for a large median lobe protruding into the bladder 
, clinically significant diverticulum or large bladder 
calculi as it allows direct access to the bladder neck and 
bladder mucosa. However, with this approach direct 
visualisation of the apical prostatic adenoma is limited 
and apical enucleation is less precise. Haemostasis may 
be more difficult due to inadequate visualisation of the 
entire prostatic fossa after enucleation. 
The retropubic approach permits enucleation of the 
hyperplastic adenoma through a direct incision of the 
anterior prostatic capsule. There is excellent anatomical 
exposure of the adenoma for complete removal. 
The urethra can be transected precisely distal to the 
adenoma for preserving continence. Clear visualisation 
of the prostate bed is possible for haemostasis, and there 
is minimal to no surgical trauma to the bladder. The 
main drawback is that direct access to the bladder is not 
possible. 
Contraindications to open prostatectomy include a 
small fibrous gland and previous pelvic surgery that 
may obliterate access to the prostate gland.4
The surgical procedures of TURP, TUIP and open 
prostatectomy are all  efficacious and result  in 
improvement of LUTS exceeding 70%. Need for blood 
transfusion is in the range of 2-5%, more following open 
and less following TUIP. Stress incontinence following 
TURP is 2.2%, TUIP 1.8% and open 10%. Risk of bladder 
neck contracture is 1.8% after open, 4% after TURP and 
0.4% after TUIP. Retrograde ejaculation occurs in 80% 
after open 65-70% after TURP and 40% after TUIP 
The  potent ia l  morbidi t ies  o f  TURP and open 
prostatectomy and the pressure to reduce hospital 
stay had provided impetus for the development of 
alternative procedures for BPH. Many new techniques 
had appeared around the turn of the century. They 
have been devised to address specific shortcomings of 
monopolar TURP and open prostatectomy. 
What are the Recognised Options of 
Surgical Treatment?
We can take reference from some international guidelines.
In EAU guidelines, TURP, TUIP and open prostatectomy 
are  the  convent ional  surg ica l  opt ions .  TUVP 
(Transurethral vaporisation of prostate) and bipolar 
resections are electrosurgical modifications of the TURP 
technique. Holmium laser enucleation of the prostate 
(HoLEP) is considered alternative to the open procedure. 
Listed in the procedural options for treatment for BPH 
in the 2010 AUA guidelines are: 
Minimally invasive therapies:
- transurethral needle ablation (TUNA)
- transurethral microwave thermotherapy (TUMT)
Surgical therapies:
- open prostatectomy
- transurethral holmium laser ablation of the prostate 
(HoLAP)
- Transurethral holmium laser enucleation of the 
prostate (HoLEP)
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- Holmium laser resection of the prostate (HoLRP)
- Photoselective vaporisation of the prostate (PVP)
- Transurethral incision of the prostate (TUIP)
- Transurethral vaporisation of the prostate (TUVP)
- Transurethral resection of the prostate (TURP)
In NICE guidelines 2010, the following options are 
mentioned:
If offering surgery for managing voiding LUTS 
presumed secondary to BPH, offer monopolar or bipolar 
transurethral resection of the prostate, monopolar 
transurethral vaporisation of the prostate (TUVP) or 
holmium enucleation of the prostate (HoLEP)
Offer TUIP or open surgery as an alternative according 
to the variation of the size of the prostate gland.  
Do not offer minimally invasive treatments (including 
TUNA, TUMT, HIFU, transurethral ethanol ablation of 
prostate and laser coagulation as an alternative
Only consider offering botulinum toxin injection into 
the prostate as part of a randomised controlled trial. 
Only consider offering laser vaporisation techniques, 
bipolar TUVP or monopolar or bipolar transurethral 
vaporisation resection of the prostate (TUVRP) as part 
of a RCT that compares these techniques with TURP. 
Among the 2669 procedures done for BPH in HA 
Hospitals in July 2009-June 2010
There were: 
2365 TURP
190 laser assisted resection of prostate/ incision of 
bladder neck 
100 TUVP
13 open prostatectomy
1 bipolar transurethral enucleation of prostate
Newer techniques can be understood according to the 
effects they intend to achieve:
1. Resection: improved ways of TUR that reduce 
bleeding and avoid TUR syndrome
2. Enucleation: as an alternative to open operation but 
avoiding an open wound and significant bleeding. 
Usually more technically demanding. 
3. Vaporisation: as an alternative to TURP but 
avoiding bleeding and TUR syndrome. However, 
there would be no tissue available for diagnosis. 
4. Coagulation: induces tissue necrosis by heating as 
an alternative to TURP but avoiding bleeding and 
TUR syndrome. Takes time for tissue shrinkage 
and sloughing for relief of obstruction. Falling 
out of favour due to post-procedure retention and 
irritation and delayed relief of obstruction. 
However, by convention, they will be discussed 
according to the different types of energy and 
technology that is involved. 
Improved Open Operations
Laparoscopic  and robotic  prostatectomies are 
techniques currently associated with the treatment of 
prostate cancer but there are reports on using these 
technologies for the treatment of LUTS. Laparoscopic 
simple prostatectomy and robotic simple prostatectomy 
can reduce the large surgical wound required for 
open prostatectomy but they are still considered 
investigational. The operation can take three to five 
hours, which is longer than traditional surgery. Blood 
loss is less and hospital stay is shorter than open 
operations. The rate and severity of complications are 
similar.5 
Modified Transurethral Electrosurgery 
TUVP monopolar
TUVP was first described by Kaplan in 1995. 2 
electrosurgical effects are combined: vaporisation and 
dessication. The cutting current is set to a maximum of 
75% higher than for a standard TURP. The rollerball 
is only useful for small glands. A grooved roller-
bar increases the number of leading edges at which 
electrovaporisation takes place and increases the 
efficiency of vaporisation. New second generation 
electrodes (thick loop) have been developed to vaporise 
and resect the prostate at the same time (TUVRP). 
TUVP has equivalent short term improvements of 
symptoms, flow rate and QoL(quality of life) indices 
with a decreased risk of TUR syndrome compared with 
monopolar TURP. However, the rates of postoperative 
irritative voiding symptoms, dysuria and urinary 
retention, as well as the need for unplanned secondary 
catheterisation, appear to be higher, as are the 
reoperation rates. TUVP is considered alternative to 
TUIP and TURP particularly for patients with bleeding 
disorders and small prostates. 
Bipolar Transurethral Electrosurgery
Bipolar resection of the prostate utilises a specialised 
resectoscope loop that incorporates both the active 
and the return electrodes. The operation is similar to 
monopolar resections. This design limits the dispersal of 
the current flow in the body which theoretically reduces 
the deleterious effects of the stray current flow. The 
electric effect on a cardiac pacemaker is also markedly 
reduced. Because the bipolar resectoscope uses normal 
saline as the irrigation fluid, the risk of TUR syndrome is 
eliminated. The depth of tissue necrosis is less compared 
with bipolar resection. However, the resecting loops are 
less durable and more expensive.6
The bipolar electrodes had been modified to a 
spherical shaped button (TURis [TUR in saline] plasma 
vaporisation) and launched in 2009 for endoscopic 
vaporisation of prostate tissue. With the plasma corona 
created at the electrode good haemostasis is achieved 
with a smooth surface left but the time for vaporisation 
is somewhat longer than resection and no tissue will be 
available for diagnosis.7
The bipolar resectoscope had been used for enucleation 
of large prostatic adenoma as popularised by Professor 
CX Liu. Enucleation with monopolar resectoscope 
carries substantial risks of TUR syndrome and is not 
preferred. Effects similar to open enucleation are 
produced with avoidance of any surgical wound. 
Morcellation is not required and the adenoma is 
devascularised by endoscopic enucleation from the 
prostate bed before being cut up into small chips with 
the bipolar resectoscope. Large glands can be removed 
quite rapidly and with minimal blood loss. The 
technique requires, however, a long learning curve.8
Laser Therapies
The use of lasers to treat BPH has been contemplated 
since 1986. 4 types of lasers have been used to treat the 
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prostate: NdYAG (Neodymium Ytrrium-Aluminium 
Garnet), HoYAG (Holmium YAG), KTP (potassium 
titanyl phosphate), and diode. They are characterised 
by their specific wavelengths, which imply specific 
absorption by water and haemoglobin. The energy 
can be delivered through a bare fibre, a right-angled 
fibre or an interstitial fibre. The energy can be used 
to achieve coagulation or vaporisation. Coagulation 
causes secondary tissue sloughing which is associated 
with tissue oedema. Vaporisation on the other hand 
dehydrates tissue and decreases heat scattered 
into tissues to cause oedema. The vaporisation and 
coagulation effect can be used in combination to effect 
resection of prostate tissues or enucleation of prostatic 
adenomas. Today, the holmium and variants of the PVP 
laser are the most common laser technologies used to 
treat prostate disease. 
NdYAG: VLAP (visual laser ablation of prostate)
1064nm laser of 40-80W is delivered over 60 seconds to 
each site using a gold-plated distal reflecting mechanism 
on a lateral firing non-contact laser fibre. The laser is 
poorly absorbed by water and haemoglobin and is 
transmitted several millimetres into the tissue with 
heating and coagulating effects. The best results are 
obtained for glands below 50-60ml because in larger 
glands significant amounts of obstructive prostatic tissue 
can be left behind. Moreover, patients with chronic UTI 
and chronic bacterial prostatitis are not good candidates 
due to risks of infection of the necrotic tissue that remains 
in situ for several weeks after the operation. Despite 
claims of good short term subjective and objective 
improvements, the treatment became characterised by 
prolonged dysuria, retention and extended need for 
catheterisation. The effect was not improved despite 
increase of power of subsequent generations to 120W. 
Combination with bladder neck incision or absorbable 
stent failed to keep the procedure from being largely 
abandoned by urologists nowadays.9
Indigo laser (one type of diode laser)
830nm low energy (2-20W) laser energy is delivered 
directly to tissue from the interstitial laser fibre tip 
that punctures the prostate. Coagulative necrosis is 
generated within the adenoma, sparing its urethral 
surface. The applicator can be inserted to coagulate 
deeper tissues. Post-procedure, the intraprostatic lesions 
will result in secondary atrophy and regression of the 
prostate lobes rather than sloughing of necrotic tissues. 
Each stab lasts 3 minutes and the whole procedure 
lasts 30-60minutes. The symptoms need 6-12 weeks 
to resolve. A postoperative catheter is required for an 
average of up to 18 days. The retreatment rate is up to 
15.4% at 12 months. It is gradually replaced by laser 
techniques that remove tissue.10
Holmium
2120nm laser is absorbed primarily by water and results 
in an optical penetration depth of 0.4mm. Various 
techniques can be employed:
HoLAP uses a 550micron side-firing laser fibre in a non-
contact mode. Intended to vaporise prostate lobes down 
to the surgical capsule resulting in a TURP-like effect.
 
HoLEP 
An end-firing fibre is used to enucleate the prostate 
adenoma, separating the adenoma from the surgical 
capsule, from apex to base, after any median lobe 
has been freed from the bladder neck. Typically the 
technology is used for larger glands that would have 
been treated surgically with an open prostatectomy. 
Generally, the results compare favourably to an open 
prostatectomy in the hands of an experienced surgeon. 
Holmium enucleation leads to a similar outcome as 
open prostatectomies for men with large glands of 
over 100ml at a significantly lower complication rate. 
Nonetheless, long term data beyond 2 years are still 
lacking. The procedure requires specialised equipment 
for morcellation. The learning curve for holmium laser 
enucleation of the prostate appears to be longer than 
that of other technologies.11
HoLRP 
Prostate adenoma is resected using a homium laser 
fibre 550 micron 80W end-fire and specially adapted 
resectoscope. Symptomatic improvements may be 
comparable to that obtained after TURP with slightly 
reduced risks of bleeding, need for transfusion and 
absence of TUR syndrome.12
Green laser photoselective vaporisation (PVP)
PVP is a form of transurethral prostatectomy performed 
using a 600 micron side-firing fibre in a non-contact 
mode. Wavelength 532nm is absorbed by both water and 
haemoglobin resulting in an optical penetration depth 
of 0.8mm. Lower energy laser (up to 80W) is generated 
from KTP (potassium titanyl phosphate) generators. 
High power laser at 120W is generated from the newer 
LBO (lithium borate) generator. Normal saline is used 
for irrigation and the goal is to create a TURP-like cavity 
after ablating the various prostate lobes down to the 
surgical capsule. Symptom scores improved consistently 
in all studies, as did the QoL scores and maximum 
urinary flow rates.13
Other lasers
Biolitec laser 980nm at 150W-200W also aims at 
achieving vaporisation. Local experience is available 
but limited. The rate of vaporisation with the side-firing 
fibre seemed to be modest.14
Thulium laser 2000nm is almost identical to holmium 
except for a continuous rather than pulse discharge of 
energy. This results in greater efficiency in cutting and 
haemostasis and is useful for resection with minimal 
bleeding.15 
Generally, transurethral laser approaches have been 
associated with shorter catheterisation time and length 
of stay, and with comparable improvement in LUTS. 
There is a decreased risk of perioperative complication 
of TUR syndrome. Information concerning retreatment 
and urethral strictures is limited due to short FUs. 
Comparison of outcomes between studies should be 
considered cautiously given the rapid evolution in 
technologies and power levels. Emerging evidence 
suggests a possible role of transurethral enucleation and 
laser vaporisation as options for men with very large 
prostate of >100g. 
Radiofrequency: TUNA
TUNA employs a cystoscope-like device. The lumen 
of the prostatic urethra is directly visualised with an 
endoscope and 2 needles are inserted from the prostate 
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lumen laterally into the prostatic adenoma. The 
generator produces low level monopolar radiofrequency 
waves of 490kHz which induce a temperature of about 
100 degree Celsius in the target area causing necrosis. 
The number of needling can be adjusted according to 
the size and length of the prostate. The urethral mucosa 
is spared and the necrotic tissue will be absorbed 
over time, thus reducing the prostate volume. TUNA 
is attractive for being safe with few perioperative 
complications . Improvements in symptoms, QoL and 
urinary flow rates are significant but do not generally 
match the results of TURP. 40% of patients have 
retention of urine within the first 24 hours. Treatment 
by other modalities can be expected in 14% of patients 
within 2 years. 20% underwent TURP in 3 years. TUNA 
works best for lateral lobe enlargements and is not 
suitable for prostates over 75ml or for isolated bladder 
neck obstruction. Like other coagulative procedures, its 
use is on the decline. 16
Microwave Thermotherapy
Transurethral microwave thermotherapy (TUMT)
Original machines were low power and generated 
t e m p e r a t u r e s  t o o  l o w  t o  a c h i e ve  a n y  e f f e c t . 
Newer TUMT devices seek higher temperatures 
(thermotherapy) as well as a transurethral approach to 
target the transitional zone. An interstitial temperature 
of 50-80degrees Celsius could be achieved and a cooling 
system to protect the bladder neck and prostatic urethra 
are required. Prostatron operates at 1296MHz and is 
capable of generating up to 80W. Prostalund is the only 
device to use an interstitial probe with three sensors to 
monitor intraprostatic temperature, thereby providing 
a mechanism to control and adjust the volume of tissue 
ablation. It operates at a frequency of 915MHz with three 
different length catheters and can deliver up to 100W. 
TUMT is effective in partially relieving LUTS secondary 
to BPH. There are various devices and protocols with 
different outcome measures, and there is no compelling 
evidence from comparator trials to conclude that one 
device is superior to another. Outpatient capability, lack 
of sexual side effects and avoidance of actual surgery 
are attractive to patients and clinicians alike. But the 
perception that the treatment lacks durability of effect 
has held back greater utilisation. A catheter is required 
for retention after treatment. High energy TUMT is 
associated with improved objective results compared 
with low energy TUMT, but with increased morbidity. 
HIFU
A beam of ultrasound can be brought to a tight 
focus at a selected depth within the body to produce 
tissue destruction without damage to the overlying 
or intervening structures. The source of HIFU is the 
piezoceramic transducer. The energy can be delivered 
trans-abdominally through a water bath or trans-rectally 
through a probe. Patients develop retention of urine for 
3-6 days. Haemospermia is observed in 80% of sexually 
active men. 43.8% men need TURP due to insufficient 
therapeutic response within 4 years. The treatment is 
unsuitable for prostates with calcifications, large middle 
lobe, or over 75ml.17
Stent
The idea of using stents for splinting the lobes of the 
prostate was derived from their original use in the 
cardiovascular system. Fabian (1980) first described the 
use of stents for obstruction by prostate. Their major 
role was likely to be in patients unfit for surgery, where 
the alternative would be long term indwelling urethral 
or suprapubic catheterisation. 
Temporary: can be nonabsorbable or biodegradable. 
They are for short term use to act as an alternative to 
indwelling caths. The newer generation of temporary 
stents includes the Memokath, which is made of nitinol 
(nickel titanium alloy), with the property of shape 
memory, heat expandable at 45-50 degrees Celsius. This 
property allows the Memokath to maintain position 
better. Close contact of wires prevents ingrowth of the 
epithelium. It may be left in place up to 36 months. It 
comes at a calibre of 22Fr and a length choice of 35-
95mm. 80% remains successful at 3 months. 
Permanent: 
The Urolume endourethral prosthesis is a woven 
tubular mesh that maintains its position in the urethra 
by outward external pressure. The original device had 
a calibre of 42Fr and varied in length from 1.5 to 4cm. 
Epithelialisation occurs ideally in a smooth manner, 
covering the wires of the mesh. Severe irritative 
symptoms were common up to 3 months. Migration of 
the stent, encrustation and hyperplasia of epithelium can 
occur. Removal was eventually required in 47% and most 
removals occurred in the first 2 years. (Masood 2004) 
Injection Therapies
Injection with alcohol to effect coagulative necrosis 
of prostatic tissue and injection with botulinum toxin 
to induce atrophy of smooth muscle fibres in the 
prostate gland had been proposed for relief of outflow 
obstructions related to prostate. These measures are still 
investigational at best. 
Conclusion
Urologists are renowned for being able to capitalise 
on advances in technologies. Not surprisingly, the 
same resourcefulness is evident in our pursuit of better 
ways to serve our patients with BPH. We need to keep 
our minds open for new techniques, and at the same 
time be very meticulous in scrutinising their efficacy 
and safety. In Hong Kong, urologists are privileged 
to have exposure and access to various new surgical 
modalities for BPH. With a diversified armamentarium 
in hand, we are in a better position to individualise our 
surgical treatment for our BPH patients according to 
their disease severity, their physical condition and their 
expectation. 
“Plus ca change, plus c'est la meme chose.” (The more 
things change, the more they are the same.)
Alphonse Karr 1808-90
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Prostate cancer incidence has been rising in the last 
decade in Hong Kong. In 2008, prostate cancer was 
the third most common cancer with 1,369 new cases 
and the fifth major cause of death which killed 282 
patients.1 As the community becomes more aware of the 
disease, more patients are screened for prostate cancer. 
Serum prostate specific antigen (PSA) and digital rectal 
examination (DRE) are the 2 commonest methods 
employed for the purpose. With the advances in prostate 
cancer diagnostics and state-of-the-art treatment options 
of early prostate cancers, it is hoped that prostate cancer 
mortality will decline in the next decade. In this article, 
the author would like to focus on the update of PSA 
test in prostate cancer diagnostics and the controversial 
issue of prostate cancer screening. 
PSA was first  discovered in 1960s as a gamma 
seminoprotein in seminal fluid, developed for forensic 
use in rape cases.2 It is a weak protease, which is present 
in large amounts in semen, with the physiological 
function of liquefying the semen and improving sperm 
motility. Before the PSA era, prostate acid phosphatase 
had been used as the historical male “PAP” test. It was 
not until the discovery of association between serum 
prostate antigen and prostate cancer by Wang et al at 
in 1979 that PSA was widely adopted worldwide as the 
screening test of prostate cancer. Unfortunately PSA has 
never been the ideal screening tool. Catalona et al2 had 
suggested 4ng per ml as the optimal cut-off for early 
detection of prostate cancer. Recent studies had shown 
that there was no single cut-off value which could attain 
the likelihood ratio required of a screening test.3 The 
sensitivity and specificity of PSA at cut-offs of 3, 4 and 
5ng per ml was 59 and 87%, 44 and 92%, 33 and 95% 
respectively. The exception was PSA cut-off at 1ng per 
ml, which had a negative likelihood ratio of 0.08 and 
virtually ruled out prostate cancer diagnosis3.
There had been multiple attempts to enhance the 
accuracy of PSA test and reduce unnecessary prostate 
biopsies.2 Free to total PSA ratio less than 10% was 
associated with increased risks of malignant disease 
while ratio more than 25% was suggestive of benign 
pathology. However, many patients lied in the gray 
zone between 10 and 25%. Age-specific PSA was 
associated with decreased specificity for young patients 
and decreased sensitivity for old ones. PSA density was 
an attempt to balance out the influence of large prostate 
volume. However, there were both inter- and intra-
observer variations in prostate volume assessment. 
PSA velocity higher than 0.75ng per ml every year 
was predictive of prostate cancer, but it required 
multiple PSA tests and its subsequent calculation 
was not welcomed in routine clinical practice. Urine 
markers were promoted over the last few years as 
supplementary tests to PSA. PCA3 is now commercially 
available. PCA3 is a gene identified by Bussemakers 
et al at the University of Nijmegen, the Netherlands 
and Johns Hopkins Hospital.2 This gene is 60 to 100-
fold overexpressed in 95% of prostate cancers. The test 
measures the expression of PCA3 gene in cells isolated 
from the urine of men after receiving a meticulous 
digital rectal examination, as a function of the expression 
of PSA gene controls for the total number of prostate 
cells in the sample. PCA3 has sensitivity of 50 to 75% 
and specificity of 80 to 90%. Its potential use includes 
the difficult scenario when patients have persistently 
elevated PSA and negative previous biopsies. 
Prostate cancer screening is commonly practised in the 
United States. It is controversial in deciding whether 
its routine practice reduces prostate cancer mortality. 
In 2009, two independent large-scale randomised 
controlled trials had been published in Europe (ERSPC 
trial) and the United States (PLCO trial).4 The ERSPC 
trial6 included seven European countries with a total of 
162,387 participants. With PSA cut-off at 3 to 4ng per 
ml and follow-up of nine years, the screening group 
was shown to reduce prostate cancer mortality by 20% 
in the age group of 55 to 69 years. The PLCO trial7 
included ten US study centres with a total of 76,693 
participants. With PSA cut-off at 4ng per ml and follow-
up of ten years, there was no difference in prostate 
cancer mortality between the screening and control 
groups, at the age group of 55 to 74 years. However, 
the control group was found to be contaminated with 
prior PSA screening in up to 50% of participants. In 
2010, Cochrane review reported meta-analyses of five 
randomised controlled trials since 2006, with a total of 
341,351 patients.5 There was no reduction in all-cause or 
prostate-cancer specific mortality. Only ERSPC showed 
a reduction in prostate cancer-specific mortality in the 
age group of 55 to 69 years (RR 0.80, 95% C.I. 0.65-0.98). 
However, it needed to screen 1,410 participants, treat 48 
prostate cancer patients in order to prevent one prostate 
cancer death at ten years later. It was commented that 
men with life expectancy less than 10 to 15 years should 
think twice before PSA screening. PSA screening was 
associated with a high false positive rate of PSA tests e.g. 
with PSA cut-off at 3ng per ml, the false positive rate 
was 75.9% in ERSPC trial. Screening was associated with 
over-diagnosis of clinically insignificant disease, with 
up to 50% in PLCO trial. Patients also need to consider 
the adverse effects of prostate biopsy e.g. pain, sepsis, 
haematuria and haemospermia, etc. 
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In conclusion, PSA remains the commonest screening 
test of prostate cancer. Various tests, including PCA3 
urine markers, have been developed to enhance the 
accuracy of PSA test, in order to reduce unnecessary 
prostate biopsies. Population-based prostate cancer 
screening has not been shown to reduce disease-specific 
nor all-cause mortality. Individual patients need to 
be counselled about the pros and cons of PSA test, 
associated morbidities of prostate biopsies and prostate 
cancer treatments, especially in those elderly patients 
with a life expectancy of less than 10 years.
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Introduction
Prostate cancer is a common male malignant disease 
worldwide. Its incidence rate varies widely between 
countries and ethnic populations. The incidence rates in 
Asian countries are much lower compared to Western 
countries. Environmental exposure, diet and lifestyle, as 
well as quality of the health care system and penetrance 
of prostate specific antigen (PSA) screening affect the 
reported incidence rates. In Hong Kong, prostate cancer 
ranked the third most common male cancer and the fifth 
major causes of male cancer death in 2008.1 Over 1300 
cases of prostate cancer were diagnosed in 2008. 
Treatment Options and Considerations
The widespread use of PSA has resulted in a remarkable 
stage migration in the past decade. There is an 
increasing proportion of patients with prostate cancer 
being diagnosed at an early and potentially curable 
stage. Prostate cancers also exhibit a wide spectrum 
of aggressiveness. Therefore, the preferred method of 
treatment remains controversial. 
Treatment options for localised prostate cancers 
include active surveillance, surgery and radiation 
therapy (external beam or Brachytherapy). However, 
the treatment outcomes in any method are difficult to 
compare among studies because the populations of 
patients are usually not strictly comparable and the 
outcome measurements are not necessarily comparable 
between different forms of therapy.
In general, three significant factors contribute to the 
selection of therapy: (1) the overall life expectancy of 
the patients as determined by age and co-morbidities; 
(2) the biological characteristics of the tumour and 
prognostic information predicted from the Gleason 
grade, PSA level and clinical stage (e.g. using Partin 
tables or MSKCC Prostate Cancer Nomograms); and 
(3) the preferences of patients with consideration of 
complications, relative efficacy and quality-of-life issues.
Surgical Therapy
Radical prostatectomy requires complete removal of the 
prostate and seminal vesicles. It is the only treatment 
for localised prostate cancer that has shown a cancer-
specific survival benefit when compared with watchful 
waiting in a prospective randomised trial.2 It is indicated 
in patients with low and intermediate risk localised 
prostate cancer (cT1a-T2b, Gleason score ≤7, and PSA 
≤20) and a life expectancy of >10 years, and also in 
selected patients with low volume high risk localised 
prostate cancer (cT3a or Gleason 8-10 or PSA >20). Pelvic 
lymph node dissection can also be performed at the 
same time in selected patients with a risk of lymph node 
metastases.
Currently there are 3 approaches for radical prostatectomy, 
namely
• Radical Perineal Prostatectomy 
• Radical Retropubic Prostatectomy
• Laparoscopic Prostatectomy, with or without 
   Robot-assisted
Radical Perineal Prostatectomy
This procedure was first described by Young in 1905.3 It 
was the first method used to remove the prostate as part 
of cancer therapy. The advantages of this procedure 
include a small perineal incision with better cosmesis, 
less blood loss, less pain and quicker recovery. It also 
allows precise watertight urethrovesical anastomosis 
under direct vision. However, this procedure has fallen 
out of favour due to the disadvantages of requiring 
specialised instruments and unable to perform pelvic 
lymph node dissection (PLND) and it is not suitable for 
large sized prostates. There is also a higher rate of rectal 
injury and occasional post-operative faecal incontinence.
Radical Retropubic Prostatectomy
In 1947, Millin first described radical retropubic 
prostatectomy (RRP).4 This procedure is preferred over 
perineal prostatectomy because urologists are more 
familiar with the retropubic anatomy and the retropubic 
approach also allows an extraperitoneal pelvic lymph 
node dissection to be performed as staging purpose. 
However, this operation is fraught with possible 
massive blood loss.
In 1982, Walsh defined the peri-prostatic, vascular, and 
erectile neural anatomy and developed the technique of 
nerve-sparing radical prostatectomy.5 The description 
and characterisation of the Santorini plexus has much 
reduced the operative blood loss and transfusion rate. 
In addition, the introduction of nerve-sparing technique 
has dramatically decreased the 2 most significant 
associated morbidities i.e. incontinence and impotence. 
Laparoscopic Prostatectomy, Non-robotic and 
Robot-assisted
Minimally invasive surgical approach to treat prostate 
cancer was first described by Schuessler in 19976 who 
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performed the first successful laparoscopic radical 
prostatectomy (LRP). However, this technique did 
not gain widespread acceptance as the procedure was 
technically extremely difficult. The initial series of 9 
cases reported the operative times ranged from 8 to 11 
hours. They concluded that this laparoscopic approach 
offered no significant advantage over open surgery.
The laparoscopic approach regained attention when two 
French groups (Guillonneau and Vallancien7 and Abbou 
et al8) reported on their techniques and early results 
in 1999 and 2000 respectively. The modified technique 
resulted in a shortening of operative time to 4-5 hours 
and a mean blood loss of 400ml. However, even in 
the hands of the skilled, this was still a technically 
demanding procedure with a steep learning curve. With 
further advances in technology with improved optics 
and new laparoscopic instruments such as ultrasonic 
cutting and coagulating devices etc., LRP began to gain 
acceptance and was performed increasingly in several 
high volume centres worldwide.
The introduction of Robotic Surgical System (Da Vinci 
Surgical System) into the field of urology has made 
another great advancement on minimally invasive 
prostatectomy. The first reported robot-assisted 
laparoscopic prostatectomy (RALP) using the DaVinci 
system was described by Abbou et al in 2001.9 Menon et 
al from the Vattikuti Urology Institute are responsible 
for the development and popularisation of robotic 
radical prostatectomy.10, 11 This technique has been 
gaining widespread acceptance in the United States and 
Europe and is increasing in penetration worldwide. 
In Hong Kong there are already a few Systems (total 
of 5) installed in both public and private Hospitals for 
service since 2005.This master-slave system composed 
of a remote surgeon console and a surgical robotic arm 
system. 
The surgeon console consists of the followings:
-  Display system: a 3-dimensional stereoscopic display    
   for the console surgeon
-  Master arms: the surgeon’s thumbs and index fingers     
   can hold and move the master arms that precisely    
   translate to real-time movements of the robotic arm      
   instruments under the vision of the 3D laparoscope. 
The surgical robot arms have a camera arm for camera 
manipulation and two or three working arms, where 
different types of manipulation instruments (Endowrists) 
can be attached and interchanged during the operation.
The robot assisted laparoscopic technique provides a 
superb 3-dimensional stereoscopic vision with depth 
perception to the surgeon. Secondly, the movements of 
the robotic instrument are highly flexible and precise 
with the presence of articulated tips, it permits 7 degree 
of freedom in movement and mimicking human wrist 
movements, which is controlled by the console surgeon. 
Thirdly, the robotic system provides increased precision 
by filtering hand tremors, providing magnifications, and 
providing scaling for the surgeon’s movements. These 
result in decreased fatigue and shortened the learning 
curve of performing this operation for surgeons.   
In general, minimally invasive prostatectomy (laparoscopic 
or robot assisted) could offer the advantage of less blood 
loss, less postoperative pain, less analgesic requirements 
and quicker recovery.  
 
Complications and Management
Intra-operative and Early Complications
Haemorrhage can occur during and after radical 
prostatectomy. The average estimated blood loss in 
open RRP varies from 200 to 1500ml, depending on the 
size of the prostate, pelvic anatomy, surgical technique 
and length of operation. LRP and RALP are associated 
with less blood loss due to the tamponade effect of 
pneumoperitoneum and resulted in a much lower 
transfusion rate of less than 3%.12, 13, 14
Rectal injury is uncommon during LRP and RALP 
(0.7% to 2.4%). Anastomotic leakage is usually minor 
and can be managed conservatively by prolonged 
catheterisation. Deep vein thrombosis and pulmonary 
embolism occur in about 1.6% of patients. Elastic 
stockings,  early mobilisation and prophylactic 
anticoagulation can reduce the rate of thromboembolic 
events.
Other early complications include wound problems, 
post-operative ileus, urinary tract infection and 
lymphocoele formation.
Late Complications
The important long term problems after prostatectomy 
are erectile dysfunction and urinary incontinence. 
Accumulating surgical experience could reduce the 
frequency of these complications as observed in large 
series from high volume centres. However, comparison 
of published series is difficulty because of differences 
in patient populations, definition of outcomes and 
methods of assessment.
Recovery of erectile function after radical prostatectomy 
depends on the patient’s age, pre-operative erectile 
function and the extent of nerve-sparing surgery. In 
patients with normal pre-operative potency, potency 
is retained in 68% of patients who have undergone 
bilateral nerve-sparing and in 13-47% of men who 
have undergone unilateral nerve-sparing operation.15 
Good results with erectile function after both minimally 
invasive approaches have been reported. Guillonneau 
et al16 showed a potency rate of 66% at 12 months after 
bilateral nerve-sparing LRP, while Joseph et al achieved 
a potency rate of 68% at 6 months after bilateral nerve-
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sparing RALP. Moreover, erectile rehabilitation 
programmes using intracavernosal injection therapy 
or PDE-5 inhibitors have been shown to enhance the 
recovery of erectile function.
Urinary continence after RRP is generally good but 
varies with the experience and skills of the surgeon. Age 
is also an important independent factor affecting the 
post-op urinary incontinence rate for a higher chance of 
incontinence (usually manifested as stress incontinence) 
was noted for patients operated at an age older than 65. 
Many high-volume centres could achieve more than 
90% continence rate. Although laparoscopic approach 
again enables better visualisation of the operative 
field for more precise dissection of the prostatic apex 
and periurethral striated sphincter, published studies 
did not show significant differences in the continence 
rates.16,17 Technical modifications in LRP or RALP 
such as rhabdosphincter reconstructions have only 
shown some improvement in early continence in some 
studies.18,19 Kegel or pelvic floor exercises should be 
implemented early after surgery to increase the strength 
of external sphincter muscles.
Anastomotic strictures are uncommon complications 
with the laparoscopic approach (0% to 3%). It should be 
managed with self dilatation or intermittent dilatations 
by urologists. Internal incision or transurethral resection 
of scar tissue may be necessary but having a higher risk 
of incontinence.
Prognosis and Outcomes
The principal objective of radical prostatectomy is to 
completely excise the cancer. Radical prostatectomy 
allows accurate prediction of prognosis according 
to pathologic cancer features. Adverse pathological 
prognostic factors include non-organ confined disease, 
perineural or lymphovascular invasion, extra-capsular 
tumour extension, positive surgical margins, seminal 
vesical invasion, and lymph node metastases. A 
rising serum PSA level is usually the earliest evidence 
of tumour recurrence after radical prostatectomy. 
Therefore, biochemical recurrence is frequently used 
as an intermediate endpoint for treatment outcome. 
The actuarial 10-year cancer progression-free survival 
probability was approximately 90% for patients with 
organ-confined disease, 70% for men with extra-capsular 
tumour extension without cancerous surgical margins, 
60% for men with extra-capsular tumour extension and 
cancerous surgical margins, 30% for patients with seminal 
vesicle invasion, and 15% for patients with lymph node 
metastases. Reported oncological outcomes for LRP and 
RALP are comparable with those of open series, although 
long term oncological data are limited.20,21, 22
Conclusion
The literatures support improved operative and 
perioperative parameters with minimally invasive 
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techniques, including reduced blood loss, shorter 
hospital stay and shorter post-operative catheterisation 
time. In addition, both laparoscopic and robotic radical 
prostatectomies seem to have comparable outcomes for 
functional parameters, namely potency and continence, 
compared with open prostatectomy. Reported 
oncological outomes for laparoscopic and robotic 
radical prostatectomies are also comparable with those 
of open series, although long term oncological data are 
currently limited. The significant question that remains 
unanswered pertains to the cost-effectiveness of RALP 
compared with open and LRP. Nevertheless, minimally 
invasive radical prostatectomy is a desirable treatment 
for clinically localised prostate cancers.
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Prostate cancer is one of the most common cancers in 
men; with an incidence of 1369 new cases in 2008 (crude 
incidence rate 41.5 per 100000 people) in our locality, 
and it is now the third most common cancer in males in 
Hong Kong.1 Despite the fact that the disease is a highly 
curable disease if diagnosed at an early stage, still 
many people will suffer from advanced and metastatic 
disease, with about 300 patients died of the disease in 
2008 in Hong Kong. 
Both normal and malignant prostatic cells are dependent 
on androgens for growth, function and proliferation. 
Therefore, androgen deprivation therapy (ADT) has 
been used as the mainstay to treat advanced stage 
disease. Androgen mainly comes from the testicles, 
which produce testosterone (up to 95% of all androgens) 
and the adrenal glands (dehydroandrosterone, 
dehydroandrosterone sulphate and androstenedione). 
The testicles, and to a lesser extent, the adrenal 
glands are under control of the pituitary gland. The 
hypothalamic-pituitary-testis axis is the main target 
for ADT. Commonly used ADT is castration by either 
bilateral orchidectomy or lutenising hormone-releasing 
hormone (LH-RH) agonist administration. Both 
treatments can effectively decrease serum testosterone 
to less than 50ng/dL. Bilateral orchidectomy (surgical 
castration) is still considered as the “gold standard” for 
ADT in prostate cancer. The surgical approach can be 
total (removing both testes) or subcapsular (removing 
only the seminiferous tubules of the testis); and can be 
done under even under local anaesthesia. It provides 
the fastest action amongst all ADT and achieves the 
castration level within 12 hours. The side effects of 
bilateral orchidectomy include the intrinsic risks related 
to anaesthesia and surgery. Also some patients may 
not accept the concept of castration (loss of the “male-
image”). 
U n d e r  n o r m a l  p h y s i o l o g i c a l  c o n d i t i o n s ,  t h e 
hypothalamus secretes luteinising hormone-releasing 
hormone (LH-RH) in a pulsating manner to simulate 
the secretion of luteinising hormone (LH) from the 
pituitary. Therefore by giving an injection of an LH-RH 
analogue, the constant serum level of LH-RH will mask 
the pulsating stimulation of LH-RH to the pituitary and 
hence results in a drop in testosterone level. Currently 
there are several LH-RH analogues with different dosing 
frequencies (from 1 month to up to 1 year) available 
for usage.2 In general, the usage of LH-RH analogues is 
quite safe with no major specific side effects. However, 
if patients have advanced disease, such as bone 
metastases, it will be safer to start the patient first on 
antiandrogen (androgen receptor blockers) at least 2-3 
weeks prior to commencement of LH-RH analogues 
to avoid the “flare” phenomenon. This condition is 
related to a sudden increase in serum LH-RH analogue 
level after the initial injection and will lead to a strong 
stimulation to the pituitary and hence excessive release 
of LH and testosterone production. The development of 
an LH-RH antagonist, Degarelix, which has been shown 
to cause rapid and significant reductions in testosterone 
and prostate-specific antigen (PSA) levels, without the 
“flare” phenomenon as the LH-RH agonists.3 This rapid 
onset of action is particularly relevant in patients with 
symptomatic disease who require a more rapid effect of 
ADT. 
While  ADT provides very effect ive control  of 
prostate cancers, it also has certain side effects that 
may have long-term consequences to patients.4 
The early side effects of ADT include loss of libido, 
erectile dysfunction, hot flush, mood changes etc. 
After prolonged usage, patients may suffer from 
osteoporosis, increase in metabolic complications – such 
as dysglycaemia, dyslipidaemia, and also increased 
cardiovascular morbidities and mortalities. The long-
term side effects are particularly important for those 
patients who have slow disease progression. Therefore, 
currently there are suggestions that the intermittent 
usage of ADT may provide a balance on disease control 
and the quality of life of the patients.5 However, further 
studies are needed to define the specific group and 
protocol for the application of this intermittent therapy 
in clinical practice. 
Unfortunately, despite the effectiveness of these 
treatments, there are still a proportion of patients who 
will develop further disease progression and ultimately 
succumb as a result of advanced disease. Anti-androgen 
receptor blockers (anti-androgens, e.g. bicalutamide, 
flutamide, etc) could be used to further block the 
androgen receptors, which will help to minimise the 
effects of adrenal androgen on the tumour cells and lead 
to a drop in serum prostate specific antigen and disease 
control. Unfortunately, the effects of anti-androgen 
typically result in only a transient response in terms of 4 
to 6 months only. Then these patients will be considered 
as in a “hormonal refractory stage”. Classically, the 
patients may try some further hormonal manipulation, 
including anti-androgen withdrawal, oestrogen, steroids 
etc.6 However, the response rate is usually low and also 
with only a short duration. 
After the failure of ADT, chemotherapy will be the other 
treatment modality for these patients, in particular 
for those with relative good general condition. 
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Mitoxantrone, estramustine and doctetaxel are three 
chemotherapy agents currently approved by FDA for 
first line treatment in hormonal refractory patients. 
Recent studies have established the combination of 
Docetaxel and prednisolone as the standard of care for 
these patients.7,8 The tolerability of docetaxel is relatively 
good, except for the risk of marrow suppression. 
Various other combinations of chemotherapy have 
been used with doxitacexal, but none has demonstrated 
superiority to the docetaxel/ prednisolone combination. 
Newer chemotherapy, cabazitaxel, has also been 
approved by the FDA for the treatment of hormone-
refractory prostate cancers in 2010.9
Sipuleucel-T immunotherapy is a vaccine-based 
immune therapy. It consists of two prostate cancer cell 
lines that have been modified to secrete granulocyte-
macrophage colony–stimulating factor (GM-CSF), 
which is an immune stimulatory cytokine that plays a 
key role in stimulating the body’s immune response.10 
Although FDA has already approved this drug for use 
in hormonal refractory prostate cancers, analyses for 
its real benefits are still underway and it is also very 
expensive. 
For those patients with bony metastases, external 
beam radiotherapy can be employed for the control of 
symptoms. Also for patients with known metastases to 
the spine and long limb bones, prophylactic irradiation 
may be considered to decrease possible future 
complications such as fractures, cord compression etc. 
Bisphosphonates are potent inhibitors of bone 
resorption. Data have shown that they significantly 
reduce skeletal complications in patients with bone 
metastases from a variety of solid tumours.11 Zoledronic 
acid is the most potent bisphosphonates available, and is 
the only bisphosphonate shown to reduce the incidence 
and time to the development of skeletal-related events 
(SREs) in metastatic prostate cancers.12 Besides the use 
of zoledronic acid in the metastatic stage, there are also 
a few studies suggesting that zoledronic acid can also 
help in preventing ADT-related bone loss.13,14
In recent years, there are many breakthroughs in 
the understanding of the development of various 
stages of prostate cancer, in particular the hormonal 
failure stage. In fact, there are many new proposed 
mechanisms to account for the development of the 
hormonal refractory stage, including the self production 
of androgen (autocrine action), the up-regulation of 
androgen receptors to adapt to the low androgen stage 
etc. Therefore, the most appropriate description of this 
stage of disease is “castration refractory”, rather than 
“hormonal refractory”, as the tumour is still responsive 
to the stimulation of androgen. These new observations 
have led to the development of many new agents 
that will target on these castration-refractory prostate 
cancers.15
Abiraterone acetate is a potent and highly selective 
irreversible inhibitor of cytochrome P-17, a dual enzyme 
that blocks adrenal androgen production. Studies have 
shown that despite being “hormone refractory”, prostate 
cancer cells continue to express high androgen receptor 
expression. Use of Abiraterone and prednisolone has 
shown to slow down the disease progression, with good 
patient tolerance.16 MDV3100 is a novel AR antagonist 
selected for activity in prostate cancer cells. It blocks 
nuclear translocation of AR and DNA binding, and 
has no agonist activity when AR is over-expressed. 
Preliminary studies have shown favourable tumour 
response. Further data are awaited.17
In summary, with further understanding on the 
pathophysiology of prostate cancer cells, those patients 
who progress after orchidectomy or traditional LH-
RH antagonists are still “hormone responsive”. Newer 
agents are being developed to target these cancer cell 
characteristics and more options will be expected for 
CRPC in the future.
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FRI3
Department of Surgery, Hong 
Kong Sanatorium & Hospital
Tel: 2835 8698    Fax: 2892 7511
1 CME Point (Active)
Joint Surgical Symposium - Refinement of Reconstructive Surgery
Organisers: Department of Surgery, The University of Hong Kong & Hong Kong 
Sanatorium & Hospital, Chairman: Dr. CHAN Yu Wai, Speakers: Dr. George LI & Dr. 
Gregory LAU, Venue: Hong Kong Sanatorium & Hospital
8:00 am – 9:00 am
TUE7
Ms. Cathy CHIU 
Tel: 9464 9189
2 CME Points
HKMA - Tai Po Community Network – Hypertension and Beyond: From Better 
Management to Providing Greater Cardio-Renal Benefits
Organiser: HKMA - Tai Po Community Network, Speaker: Dr. WONG Bun Lap 
Bernard, Venue: Taipo, N.T. 
1:30 pm 
THU9
Miss Candice TONG
Tel: 2527 8285
1.5 CME Points
HKMA – Kowloon East Community Network – Management of Type 2 Diabetes 
Mellitus and Role of DPPIV Inhibitors
Organiser: HKMA – Kowloon East Community Network, Chairman: Dr. AU Ka Kui 
Gary, Speaker: Dr. YAU See Yun Joyce, Venue: Lei Garden Restaurant, Shop L5-8, APM, 
418 Kwun Tong Road, Kwun Tong, Kowloon
1:00 pm 
Miss Candice TONG
Tel: 2527 8285
1 CME Point
HKMA HKE – Acute Hepatitis When to Refer for Liver Transplantation
Organiser: HKMA HKE Community Network, Chairman: Dr. NGAN Sze Yuen Silas, 
Speaker: Dr. CHOK Siu Ho, Venue: HKMA Head Oﬃce, 5/F., Duke of Windsor Social 
Service Building, 15 Hennessy Road, Hong Kong
1:00 pm 
HKMA CME Department
Tel: 2527 8452
1 CME Point
HKMA Structured CME Programme with Hong Kong Sanatorium & Hospital Year 
2011 – Bleeding & Thrombotic Tendencies
Organiser: The Hong Kong Medical Association, Dr. TSANG Kin Lun, Speaker: Dr. MA 
Shiu Kwan Edmond, Venue: The Hong Kong Medical Association Central Premises, Dr. 
Li Shu Pui Professional Education Centre, 2/F., Chinese Club Building, 21-22 Connaught 
Road Central, Hong Kong 
2:00 pm 
Ms. Candy YUEN
Tel: 2527 8285
Choir Performance in HA Convention Opening Ceremony
Organiser: The Hong Kong Medical Association, Venue: HK Convention & Exhibition 
Centre, Wanchai, Hong Kong 
8:30 am 
Ms. Sonia CHEUNG 
Tel: 2527 8898    Fax: 2865 0345
FMSHK Officers’ Meeting
Organiser: The Federation of Medical Societies of Hong Kong,   Venue: Gallop, 2/F., 
Hong Kong Jockey Club Club House, Shan Kwong Road, Happy Valley, Hong Kong 
8:00 pm – 10:00 pm
Ms. Christine WONG
Tel: 2527 8285
Council Meeting
Organiser: The Hong Kong Medical Association, Chairman: Dr. CHOI Kin, Venue: 
HKMA Head Oﬃce, 5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, 
Hong Kong
9:00 pm 
MON6 Miss Alice TANG & Miss Sharon HUNGTel: 2527 8285
Tuen Ng Dragon Boat Races 
Organiser: The Hong Kong Medical Association, Venue: Stanley Main Beach
8:00 am 
WED8
Miss Candice TONG
Tel: 2527 8285
Max 5 CMP Points 
Dr. Gilberto LEUNG
Tel: 2255 3368    Fax: 2818 4350
1.5 CME points
Certificate Course on Management of Drug Abuse Patients for Family Doctors (HK 
Island) – Session 5 & 6 
Organisers: HKMA Beat Drugs Action Committee; HKMA CW&SCN and HKMA 
HKECN, Chairmen: Dr. TSANG Chun Au; Dr. LAW Yim Kwai & Dr. YIK Ping Yin, 
Speakers: Various, Venue: The Hong Kong Medical Association Central Premises, Dr. Li 
Shu Pui Professional Education Centre, 2/F., Chinese Club Building, 21-22 Connaught 
Road Central, Hong Kong 
12:45 pm 
Hong Kong Neurosurgical Society Monthly Academic Meeting – Slit Ventricle Syndrome
Organiser: Hong Kong Neurosurgical Society, Chairman: Dr. LUI Wai Man, Speaker: Dr. 
Rebecca NG, Venue: Seminar Room, Ground Floor, Block A, Queen Elizabeth Hospital, 
Kowloon 
7:30 am 
FRI10
Miss Candice TONG
Tel: 2527 8285
HKMA Shatin Doctors Network – Gastroenterology and Hepatology Updates-Case 
Sharing for Better Liasion Between Gastroenterologists and General Practitioners
Organiser: The Hong Kong Medical Association, Chairman: Dr. MAK Wing Kin, 
Speaker: Dr. YEUNG Hon Cheung, Venue: Royal Park Hotel, Shatin, N.T. 
1:00 pm 
SAT11
Ms. Clara TSANG
Tel: 2354 2440
2 CME Points 
Refresher Course for Health Care Providers 2010/2011
Organiser: The Hong Kong Medical Association, Speaker: Dr. WONG Tak Cheung, 
Venue: OLMH
2:00 pm 
SUN12
HKMA CME Department
Tel: 2527 8452
3 CME Points
HKMA Certificate Course on Family Medicine 2011
Speakers: Prof. Albert LEE & Dr. KWONG Bi Lok Mary, Venue: QEH 
2:00 pm 
MON
SAT
THU
13
Ms. Candy YUEN
Tel: 2527 8285 
HKMA Choir Rehearsal
Organiser: The Hong Kong Medical Association, Chairman: Dr. YS CHAN & Dr. YM 
NG, Venue: GP1, HKCC
8:00 pm 
Dr. HUNG Hing Hoi / 
Ms. Tammy HUNG 
Tel: 2958 6006 / 9609 6064
1 CME Point 
Non-functioning Kidney which Requires 3 Operations
Organiser: Hong Kong Urological Association, Chairman: Dr. CHUI Ka Lun, Speaker: 
Dr. Mandy TAM, Venue: Seminar Room, G/F, Block A, Queen Elizabeth Hospital, 
Kowloon 
7:30 pm – 8:30 pm
18
Miss Alice TANG &
Miss Sharon HUNG
Tel: 2527 8285
Hong Kong International Dragon Boat Races
Organiser: The Hong Kong Medical Association, Venue: TST East
8:30 pm 
16 Ms. Gary WONGTel: 3513 48211 CME Point
HKMA – KLN East Community Network; HA – UCH; HKCFP - CME Course for 
Health Personnel 2011
Organiser: HKMA – KLN East Community Network, Chairman: Dr. CHAO Vai Kiong 
David, Speaker: Dr. Victor ABDULLAH, Venue: UCH
1:00 pm 
Miss Alice TANG & 
Miss Sharon HUNG
Tel: 2527 8285
HKMA Tenpin Bowling Tournament
Organiser: The Hong Kong Medical Association, Venue: South China Athletic 
Association
2:00 pm 
Miss Alice TANG & 
Miss Sharon HUNG
Tel: 2527 8285
HKMA Dragon Boat Team Practice Session
Organiser: The Hong Kong Medical Association, Venue: Sai Kung
3:00 pm 
WED
Miss Candice TONG
Tel: 2527 82851 HKMA – Central, Western & Southern Community Network – Certificate Course on Psychiatry (Session 1 to 3)Organiser: HKMA - Central, Western & Southern Community Network, Chairman: Dr. 
YIK Ping Yin & Dr. TSANG Chun Au, Speaker: Various, Venue: The Hong Kong 
Medical Association Central Premises, Dr. Li Shu Pui Professional Education Centre, 
2/F., Chinese Club Building, 21-22 Connaught Road Central, Hong Kong 
Date  / Time Function Enquiry / Remarks
1:00 pm 
(15, 29)
(19)
(26)
(20,27)
(19)
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Course / Meeting
Hong Kong Surgical Forum – Summer 2011
Organiser: Department of Surgery, The University of Hong Kong; Queen Mary Hospital & Hong Kong Chapter of American 
College of Surgeons, Venue: Underground Lecture Theatre, New Clinical Building, Queen Mary Hospital, Pokfulam, Hong Kong, 
Enquiry: Forum Secretary, Hong Kong Surgical Forum, Tel: 2255 4882 / 2255 4886, Fax: 2819 3416, Email: hksf@hku.hk, Website: 
http://www3.hku.hk/surgery/forum.php 
16/7/2011
Upcoming Certiﬁcate Courses of the Federation of Medical Societies of Hong Kong
12/7/2011 - 16/8/2011
5/8/2011 - 9/9/2011
Healthcare Workers 
Paramedical Professional 
9 CNE Points; CME/CPD 
Accreditation in application
9 CNE Points; CME/CPD 
Accreditation in application
Certiﬁcate Course on 
Occupational Hygiene Practice 
Certiﬁcate Course on 
Communication and Swallowing 
Problem in the Elderly Population 
C178
C183
Date Course No Target ParticipantsCourse Name CME/CNE 
SUN19
Miss Alice TANG &
Miss Sharon HUNG
Tel: 2527 8285
HKMA Table-Tennis Tournament 2011
Organiser: The Hong Kong Medical Association, Venue: HKBU
2:00 pm 
(26)
Date  / Time Function Enquiry / Remarks
TUE21
Mr. Wilson YUEN
Tel: 9045 5114
1.5 CME Points
HKMA - Tai Po Community Network – Treatment of Major Depressive Order
Organiser: HKMA - Tai Po Community Network, Chairman: Dr. CHIU Sik Ho, Speaker: 
Dr. LEE Ting Chun Allen, Venue: Taipo, N.T. 
1:00 pm 
THU23
Miss Candice TONG
Tel: 2527 8285
1 CME Point
HKMA Hong Kong East Community Network - Concomitant Management of Obesity 
& Glycaemic Control - What are the Options cum Annual Meeting
Organiser: HKMA Hong Kong East Community Network, Chairman: Dr. WONG Bun 
Lap Bernard, Speaker: Dr. CHAN Wing Bun, Venue: HKMA Head Oﬃce, 5/F., Duke of 
Windsor Social Service Building, 15 Hennessy Road, Hong Kong
6:45 pm
WED22
Miss Candice TONG
Tel: 2527 8285
1 CME Point
HKMA Shatin Doctors Network – Lecture Series on BPH & Common Urological 
Diseases for Men after 50s’ – Common Urological Diseases in Primary Care Clinics – 
Practical Tips
Organiser: HKMA Shatin Doctors Network, Chairman: Dr. MAK Wing Kin, Speaker: 
Prof. YIP Kam Hung Sidney, Venue: Royal Park Hotel, Shatin, N.T. 
1:00 pm 
FRI24 Miss Candice TONGTel: 2527 8285HKMA Shatin Doctors Network - Hormonal Contraceptives in General PracticeOrganiser: HKMA Shatin Doctors Network, Chairman: Dr. MAK Wing Kin, Speaker: Dr LAU Tai Wah, Venue: Royal Park Hotel, Shatin1:00 pm 
SAT25 Miss Noel YEUNG /Miss  Mandy LEUNG /Miss Candice TONGTel: 2958 8613 /  2527 8285
HKMA YTMCN and Kowloon Central Cluster – Certificate Course on Bringing Better 
Health to Our Community (Lecture 2)
Organiser: HKMA YTMCN and Kowloon Central Cluster, Speakers: Dr. CHIANG 
Chung Seung & Dr. HUI Yee Tak, Venue: Queen Elizabeth Hospital, Kowloon 
1:00 pm 
Miss Sharon HUNG
Tel: 2527 8285
HKMA Trailwalker First Briefing Session
Organiser: The Hong Kong Medical Association, Venue: The Hong Kong Medical 
Association Central Premises, Dr. Li Shu Pui Professional Education Centre, 2/F., 
Chinese Club Building, 21-22 Connaught Road Central, Hong Kong 
4:00 pm 
Ms. Sonia CHEUNG 
Tel: 2527 8898    Fax: 2865 0345
FMSHK Executive Committee Meeting  
Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council 
Chambers, 4/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, 
Hong Kong
8:00 pm – 10:00 pm
News from Member Societies
Society News
The FMSHK would like to send its congratulations to the new office-bearers and look forward to working 
together with the societies. 
Updated office-bearers of member societies: 
Name of member societies President Hon. Secretary Hon. Treasurer
Association of Private Orthopaedic Surgeons Dr. Yan-kit LAM Dr. Peter Ting-kwan LUNG Dr. Peter Ting-kwan LUNG
Hong Kong College of Health Service Executives Dr. Hok-cheung MA Ms. Tammy Mun-yee SO Dr. Shao-haei LIU
Hong Kong Institute of Medical Laboratory 
Sciences Limited
Mr. Chi-lim KWOK Mr. Wing-yin HO Mr. Bosco Wan-lung YAU
Hong Kong Practising Dietitians Union Mr. Frankie Pui-lam SIU Ms. Shi-po POON Ms. Ka-wai YIM
Hong Kong Society of Clinical Oncology Dr. Gordon AU Dr. William FOO Dr. Sai-ki O
The Hong Kong Ophthalmological Society Dr. Nancy Shi-yin YUEN Dr. Dexter Yu-lung LEUNG Prof. Dorothy Shu-ping FAN
The Hong Kong Society of Digestive Endoscopy Dr. William Sai-chik CHAO Prof. James Yun-wong LAU Prof. Ka-leung CHAN
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Answer to Dermatological Quiz
1.
2.
3.
4.
Palmoplantar pustulosis (PPP), also known as pustulosis 
palmaris et plantaris.
The main differential diagnoses include pompholyx 
(dyshidrotic eczema), contact dermatitis (such as 
housewife dermatitis), id reaction of tineal infection and 
drug-induced pustuloderma. Pompholyx and housewife 
dermatitis may have pustular lesions if superimposed by 
secondary infection, but they are often preceded by clear 
vesicles. Id reaction of tineal infection is rare and usually 
there is a known focus of distant fungal infection such as 
tinea pedis.
PPP is a chronic relapsing pustular eruptions over both 
palms and soles. In the past, it had been regarded as a 
synonym of localised palmoplantar pustular psoriasis. 
However, current findings show that PPP is likely a 
distinct entity, as only 20% of it are associated with 
psoriasis and its clinical and genetic profiles are different 
from psoriasis. PPP has a female predominance and a 
high prevalence in chronic smokers. It has also been 
reported that PPP is associated with recurrent multifocal 
osteomyelitis in adolescents. Interestingly, acropustulosis 
(previously known as acrodermatitis continua), another 
form of pustular lesions occurring mainly over the fingers 
and toes and often accompanied by nail destruction, has 
a higher risk of developing into generalised pustular 
psoriasis.
PPP is often refractory to various treatments available 
and has a high recurrence rate. Cessation of smoking is 
important. Treatments otherwise are similar to psoriasis. 
Topical potent topical steroids or calcipotriol are the first 
line agents most commonly used. In refractory cases, 
soaking PUVA (Psoralen and ultraviolet A) therapy 
has beneficial effects, which can be further enhanced 
by combining with an oral retinoid. In severe cases, 
methotrexate or cyclosporine can be used, but these 
aggressive systemic treatments need justifications. With 
regard to the biologics, studies had shown that PPP did 
not respond to TNF (tumour necrosis factor) antagonists, 
while acropustulosis did respond to these new drugs.
Dr. Lai-yin CHONG 
MBBS(HK), FRCP(Lond, Edin, Glasg), FHKCP, FHKAM(Med)
Private Dermatologist
 The Federation of Medical Societies of Hong Kong
 4/F Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, HK
 Tel: 2527 8898           Fax: 2865 0345
Patron
The Honourable
Donald TSANG, GBM  曾蔭權先生
President
Dr. LO See-kit, Raymond    勞思傑醫生
1st Vice-President
Prof. CHAN Chi-fung, Godfrey 陳志峰教授
2nd Vice-President
Dr. LO Sze-ching, Susanna 盧時楨醫生
Hon. Treasurer
Mr. LEE Cheung-mei, Benjamin  李祥美先生
Hon. Secretary
Dr. CHAN Sai-kwing  陳世炯醫生
Executive Committee Members
Dr. CHAN Chi-wing, Timmy 陳智榮醫生
Dr. CHAN Chun-kwong, Jane 陳真光醫生
Dr. CHAN Hau-ngai, Kingsley 陳厚毅醫生
Prof. CHIM Chor-sang, James 詹楚生教授
Dr. HUNG Che-wai, Terry 洪致偉醫生
Ms. KU Wai-yin, Ellen 顧慧賢女士
Dr. LEUNG Ka-kit, Gilberto 梁嘉傑醫生
Dr. MAN Chi-wai 文志衛醫生
Dr. MOK Chun-on 莫鎮安醫生
Dr. NG Yin-kwok 吳賢國醫生
Dr. WONG Mo-lin, Maureen 黃慕蓮醫生
Ms. YAP Woan-tyng, Tina 葉婉婷女士
Dr. YU Chau-leung, Edwin 余秋良醫生
Dr. YUEN Shi-yin, Nancy 袁淑賢醫生
Founder Members
British Medical Association (Hong Kong Branch)
英 國 醫 學 會 ( 香 港 分 會 )
President
Dr. LO See-kit, Raymond  勞思傑醫生
Vice-President
Dr. WU, Adrian  鄔揚源醫生
Hon. Secretary
Dr. HUNG Che-wai, Terry   洪致偉醫生
Hon. Treasurer
Dr. LEUNG, Clarence  梁顯信醫生
Council Representatives
Dr. LO See-kit, Raymond  勞思傑醫生
Dr. CHEUNG Tse-ming 張子明醫生
Tel:  2527 8898        Fax: 2865 0345
The Hong Kong Medical Association
香 港 醫 學 會
President
Dr. CHOI Kin   蔡堅醫生
Vice- Presidents
Dr. CHAN Yee-shing, Alvin 陳以誠醫生
Dr. CHOW Pak-chin 周伯展醫生
Hon. Secretary
Dr. LEE Fook-kay 李福基醫生
Hon. Treasurer
Dr. LEUNG Chi-chiu 梁子超醫生
Council Representatives
Dr. CHAN Yee-shing  陳以誠醫生
Dr. CHOW Pak-chin 周伯展醫生
Chief Executive
Mrs. LEUNG, Yvonne 梁周月美女士
Tel: 2527 8285 (General Office)
       2527 8324 / 2536 9388  (Club House in Wanchai / Central)
Fax: 2865 0943 (Wanchai), 2536 9398 (Central)
Email: hkma@hkma.org   Website: http://www.hkma.org
The HKFMS Foundation Limited  香港醫學組織聯會基金  
Board of Directors
President
Dr. LO See-kit, Raymond 勞思傑醫生
1st Vice-President
Prof. CHAN Chi-fung, Godfrey 陳志峰教授
2nd Vice-President
Dr. LO Sze-ching, Susanna 盧時楨醫生
Hon. Treasurer
Mr. LEE Cheung-mei, Benjamin  李祥美先生
Hon. Secretary
Dr. CHAN Sai-kwing  陳世炯醫生
Directors
Mr. CHAN Yan-chi, Samuel 陳恩賜先生
Prof. CHIM Chor-sang, James 詹楚生教授
Ms. KU Wai-yin, Ellen 顧慧賢女士
Dr. WONG Mo-lin, Maureen 黃慕蓮醫生
Dr. YU Chak-man, Aaron 余則文醫生
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